{"id":33749,"date":"2025-05-20T18:53:21","date_gmt":"2025-05-20T10:53:21","guid":{"rendered":"https:\/\/flcube.com\/?p=33749"},"modified":"2025-05-20T18:53:21","modified_gmt":"2025-05-20T10:53:21","slug":"pfizer-licenses-3sbios-bispecific-antibody-ssgj-707-in-global-deal-excluding-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33749","title":{"rendered":"Pfizer Licenses 3SBio’s Bispecific Antibody SSGJ-707 in Global Deal Excluding China"},"content":{"rendered":"\n

US major Pfizer Inc., (NYSE: PFE<\/a>) this week entered into a global license agreement with China-based 3SBio Inc., (HKG: 1530<\/a>), securing development, manufacturing, and commercialization rights to SSGJ-707, a bispecific antibody (BsAb) targeting PD-1 and VEGF, for all markets excluding China.<\/p>\n\n\n\n

Financial Terms<\/strong>
Under the agreement, 3SBio will receive an upfront payment of USD 1.25 billion. Additionally, 3SBio is eligible to receive milestone payments totaling up to USD 4.8 billion, contingent on achieving certain development, regulatory, and commercial milestones. The deal also includes provisions for tiered double-digit royalties.<\/p>\n\n\n\n

Clinical Development<\/strong>
SSGJ-707 is currently undergoing multiple clinical studies in China, focusing on non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. The drug has demonstrated significant anti-tumor activity and good safety profile, both as a monotherapy and in combination with other therapies. The first Phase III study is scheduled to commence in China in 2025.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US major Pfizer Inc., (NYSE: PFE) this week entered into a global license agreement with…<\/p>\n","protected":false},"author":1,"featured_media":33750,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[116,16,1061,28,863,18,309],"class_list":["post-33749","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-3sbio","tag-cancer","tag-hkg-1530","tag-multi-specific-antibodies","tag-nyse-pfe","tag-pd-1-l1","tag-pfizer"],"yoast_head":"\nPfizer Licenses 3SBio's Bispecific Antibody SSGJ-707 in Global Deal Excluding China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US major Pfizer Inc., (NYSE: PFE) this week entered into a global license agreement with China-based 3SBio Inc., (HKG: 1530), securing development, manufacturing, and commercialization rights to SSGJ-707, a bispecific antibody (BsAb) targeting PD-1 and VEGF, for all markets excluding China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33749\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Licenses 3SBio's Bispecific Antibody SSGJ-707 in Global Deal Excluding China\" \/>\n<meta property=\"og:description\" content=\"US major Pfizer Inc., (NYSE: PFE) this week entered into a global license agreement with China-based 3SBio Inc., (HKG: 1530), securing development, manufacturing, and commercialization rights to SSGJ-707, a bispecific antibody (BsAb) targeting PD-1 and VEGF, for all markets excluding China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33749\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-20T10:53:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2005.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33749#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33749\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer Licenses 3SBio’s Bispecific Antibody SSGJ-707 in Global Deal Excluding China\",\"datePublished\":\"2025-05-20T10:53:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33749\"},\"wordCount\":157,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33749#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2005.webp\",\"keywords\":[\"3SBio\",\"Cancer\",\"HKG: 1530\",\"Multi-specific antibodies\",\"NYSE: PFE\",\"PD-1\\\/L1\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33749#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33749\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33749\",\"name\":\"Pfizer Licenses 3SBio's Bispecific Antibody SSGJ-707 in Global Deal Excluding China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33749#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33749#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2005.webp\",\"datePublished\":\"2025-05-20T10:53:21+00:00\",\"description\":\"US major Pfizer Inc., (NYSE: PFE) this week entered into a global license agreement with China-based 3SBio Inc., (HKG: 1530), securing development, manufacturing, and commercialization rights to SSGJ-707, a bispecific antibody (BsAb) targeting PD-1 and VEGF, for all markets excluding China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33749#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33749\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33749#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2005.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2005.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pfizer Licenses 3SBio's Bispecific Antibody SSGJ-707 in Global Deal Excluding China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33749#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Licenses 3SBio’s Bispecific Antibody SSGJ-707 in Global Deal Excluding China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer Licenses 3SBio's Bispecific Antibody SSGJ-707 in Global Deal Excluding China - Insight, China's Pharmaceutical Industry","description":"US major Pfizer Inc., (NYSE: PFE) this week entered into a global license agreement with China-based 3SBio Inc., (HKG: 1530), securing development, manufacturing, and commercialization rights to SSGJ-707, a bispecific antibody (BsAb) targeting PD-1 and VEGF, for all markets excluding China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33749","og_locale":"en_US","og_type":"article","og_title":"Pfizer Licenses 3SBio's Bispecific Antibody SSGJ-707 in Global Deal Excluding China","og_description":"US major Pfizer Inc., (NYSE: PFE) this week entered into a global license agreement with China-based 3SBio Inc., (HKG: 1530), securing development, manufacturing, and commercialization rights to SSGJ-707, a bispecific antibody (BsAb) targeting PD-1 and VEGF, for all markets excluding China.","og_url":"https:\/\/flcube.com\/?p=33749","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-20T10:53:21+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2005.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33749#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33749"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer Licenses 3SBio’s Bispecific Antibody SSGJ-707 in Global Deal Excluding China","datePublished":"2025-05-20T10:53:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33749"},"wordCount":157,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33749#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2005.webp","keywords":["3SBio","Cancer","HKG: 1530","Multi-specific antibodies","NYSE: PFE","PD-1\/L1","Pfizer"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33749#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33749","url":"https:\/\/flcube.com\/?p=33749","name":"Pfizer Licenses 3SBio's Bispecific Antibody SSGJ-707 in Global Deal Excluding China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33749#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33749#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2005.webp","datePublished":"2025-05-20T10:53:21+00:00","description":"US major Pfizer Inc., (NYSE: PFE) this week entered into a global license agreement with China-based 3SBio Inc., (HKG: 1530), securing development, manufacturing, and commercialization rights to SSGJ-707, a bispecific antibody (BsAb) targeting PD-1 and VEGF, for all markets excluding China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33749#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33749"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33749#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2005.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2005.webp","width":1080,"height":608,"caption":"Pfizer Licenses 3SBio's Bispecific Antibody SSGJ-707 in Global Deal Excluding China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33749#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer Licenses 3SBio’s Bispecific Antibody SSGJ-707 in Global Deal Excluding China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2005.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33749"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33749\/revisions"}],"predecessor-version":[{"id":33751,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33749\/revisions\/33751"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33750"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}